Berwyn, PA, July 12, 2011 QR Pharma, Inc., a developer of novel compounds for the treatment of cognitive impairment, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, chief executive officer, will present a poster entitled “Mechanism of Action of Posiphen®: from Model to Human” at the Alzheimer’s Association International Conference on Alzheimer’s Disease in Paris, France. This conference brings together the leading scientists from around the world to collaborate and discuss the latest advances in Alzheimer’s disease research. The poster presentation (Poster #P3-160) will be held on Tuesday July 19, 2011, at 12:30 to 2:30PM.
About Posiphen®, QR’s Lead Compound
Posiphen® is a small orally active compound with high blood brain barrier permeability, which lowers levels of toxic protein aggregates. It targets the mRNA of a number of proteins that are overexpressed in several neurological disorders such as Alzheimer’s disease, Parkinson’s disease and Down syndrome. It is in clinical development as an oral treatment for Alzheimer’s disease. Posiphen reduces the rate of synthesis of amyloid precursor protein (APP) in cell cultures, normal, transgenic and trisomic mice. APP is cleaved into a number of toxic peptides, including Aβ42, which is cleaved from the middle while the others are cleaved from the N- and C- terminal ends. These peptides attack multiple pathways of neuronal cell life leading to synaptic loss and nerve cell death. This degeneration of the brain induces dysfunction, neuroinflammation and leads to cognitive impairment and neurodegeneration.
QR conducted a trial in patients with mild cognitive impairment to confirm Posiphen’s mechanism of action in humans and correlate it with the pharmacokinetics of the compound and its metabolites in CSF and plasma. Posiphen lowers levels of APP, tau and inflammation by about 50%, approaching the levels found in healthy volunteers.
We conducted a trial in MCI patients to confirm this mechanism of action (reduced rate of APP synthesis) in humans and correlate it with the pharmacokinetics of the drug and its metabolites in CSF and plasma. We found that Posiphen® and metabolites enter the brain readily and show a 2 to 2.5 time longer half-life in brain than in plasma, leading to prolonged efficacy and possible once a day dosing.
About QR Pharma, Inc.
Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment, Alzheimer’s disease (AD), Parkinson’s disease (PD) and Down syndrome (DS). QR currently has three product development programs – Posiphen for early stage AD and PD and BNC for advanced AD. For more information on QR Pharma, please visit the company’s website, www.qrpharma.com.